Canada

Health Canada is the federal department responsible for regulating health products in Canada, operating under the authority of the Food and Drugs Act (FDA) and its associated regulations, including the Medical Devices Regulations (SOR/98-282) and the Food and Drug Regulations (C.R.C., c. 870). The regulatory framework governs the safety, efficacy, and quality of pharmaceuticals, biologics, medical devices, in vitro diagnostics, and increasingly, digital health technologies. Submissions are reviewed by specialized directorates, including the Therapeutic Products Directorate (TPD), the Biologics and Genetic Therapies Directorate (BGTD), and the Medical Devices Directorate (MDD). Health Canada employs a risk-based classification system for medical devices (Classes I-IV) and requires a Market Authorization (formerly a Notice of Compliance, or NOC) for pharmaceuticals and biologics before products may be sold in Canada.

Submissions to Health Canada generally follow the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for pharmaceuticals and biologics, facilitating alignment with other major regulatory agencies such as the FDA and EMA. Foreign manufacturers are required to appoint a Canadian Importer or regulatory correspondent responsible for submissions and post-market obligations. Health Canada has introduced several modernization initiatives in recent years, including the Agile Licensing framework, which aims to enable earlier access to promising therapies through rolling review and post-market commitments. The department also participates in international work-sharing programs, such as the Access Consortium (with Australia, Singapore, Switzerland, and the United Kingdom), to streamline review workloads and accelerate market entry for qualifying products. Guidance documents and regulatory decision summaries are publicly available, promoting transparency in the review process.

Canada operates a decentralized public procurement system for health products, reflecting its federal structure in which constitutional responsibility for healthcare delivery rests primarily with the ten provinces and three territories. Each provincial and territorial ministry of health manages its own drug formulary, tendering processes, and procurement contracts for publicly funded programs. Large hospital networks and regional health authorities conduct their own device and diagnostic procurement, often through group purchasing organizations (GPOs) such as Medbuy (HealthPRO Procurement Services) and the Canadian Collaborative Procurement Initiative (CCPI), which aggregate purchasing power to negotiate pricing and standardize supply. The federal government, through the Public Health Agency of Canada (PHAC) and the Strategic National Stockpile (SNS), procures products for national emergency preparedness, pandemic response, and certain federal health programs covering populations such as Indigenous peoples, veterans, and federal inmates. Pharmaceutical pricing for patented medicines is overseen by the Patented Medicine Prices Review Board (PMPRB), which sets ceiling prices, while the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint formulary negotiations on behalf of participating provinces and territories to achieve consistent reimbursement pricing.

The private sector constitutes a significant share of health product procurement in Canada, including private insurance plans, out-of-pocket purchases, and employer-sponsored benefit programs; this channel is particularly relevant for medical devices, diagnostics, digital health solutions, and non-formulary pharmaceuticals. Canada does not rely substantially on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, or USAID, as it is a high-income donor country rather than a recipient. However, Canadian health institutions and companies may engage with these channels in the context of global health initiatives and export markets. Canada has historically not maintained explicit local manufacturing preference policies in health procurement, though the COVID-19 pandemic prompted federal investments in domestic biomanufacturing capacity, including partnerships under the Biomanufacturing and Life Sciences Strategy launched in 2021, which may influence future procurement policy and supplier prioritization for strategic health security products.